$VKTX
Viking Therapeutics, Inc.

2017 Q2 Form 10-Q Financial Statement

#000156459017017021 Filed on August 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.270M $1.210M
YoY Change 4.96% -20.92%
% of Gross Profit
Research & Development $3.716M $2.370M
YoY Change 56.79% 115.28%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.983M $3.578M
YoY Change 39.27% 36.21%
Operating Profit -$4.983M -$3.578M
YoY Change 39.27% 36.21%
Interest Expense -$1.000K -$1.813K
YoY Change -44.84% -93.92%
% of Operating Profit
Other Income/Expense, Net -$189.0K -$114.7K
YoY Change 64.72% -97.81%
Pretax Income -$5.170M -$3.690M
YoY Change 40.11% -53.11%
Income Tax
% Of Pretax Income
Net Earnings -$5.172M -$3.693M
YoY Change 40.06% -53.05%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$214.3K -$215.7K
COMMON SHARES
Basic Shares Outstanding 24.12M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.10M $17.20M
YoY Change -29.65% -20.74%
Cash & Equivalents $3.394M $5.160M
Short-Term Investments $8.700M $12.00M
Other Short-Term Assets $2.200M $1.100M
YoY Change 100.0% 83.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.30M $18.30M
YoY Change -21.86% -17.83%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $200.0K
YoY Change -50.0%
Total Long-Term Assets $0.00 $200.0K
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $14.30M $18.30M
Total Long-Term Assets $0.00 $200.0K
Total Assets $14.30M $18.50M
YoY Change -22.7% -16.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.300M $1.200M
YoY Change 8.33% 19.01%
Accrued Expenses $2.500M $900.0K
YoY Change 177.78% 350.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $2.400M
YoY Change 29.17% 41.18%
Total Short-Term Liabilities $7.700M $5.700M
YoY Change 35.09% 16.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $6.054K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.700M $5.700M
Total Long-Term Liabilities $6.054K $0.00
Total Liabilities $7.733M $5.800M
YoY Change 33.33% 18.95%
SHAREHOLDERS EQUITY
Retained Earnings -$70.67M
YoY Change
Common Stock $77.26M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.588M $12.80M
YoY Change
Total Liabilities & Shareholders Equity $14.32M $18.50M
YoY Change -22.59% -16.93%

Cashflow Statement

Concept 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$5.172M -$3.693M
YoY Change 40.06% -53.05%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.200M -$3.220M
YoY Change 30.43% 98.77%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$770.0K -$4.830M
YoY Change -84.06% -60.31%
Cash From Investing Activities -$770.0K -$4.830M
YoY Change -84.06% -60.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $7.800M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.010M 9.260M
YoY Change -56.7% -59.69%
NET CHANGE
Cash From Operating Activities -4.200M -3.220M
Cash From Investing Activities -770.0K -4.830M
Cash From Financing Activities 4.010M 9.260M
Net Change In Cash -960.0K 1.210M
YoY Change -179.34% -86.82%
FREE CASH FLOW
Cash From Operating Activities -$4.200M -$3.220M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
34894
CY2017Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
3050427
CY2016Q4 vktx Debt Conversion Feature Liability Current
DebtConversionFeatureLiabilityCurrent
731048
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6476534
CY2017Q2 us-gaap Interest Payable Current
InterestPayableCurrent
59333
CY2017Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6054
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
16307
CY2017Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6054
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
16307
CY2017Q2 us-gaap Liabilities
Liabilities
7733032
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
277
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
77264402
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-5999
CY2017Q2 vktx Convertible Notes Payable Discount Current
ConvertibleNotesPayableDiscountCurrent
919184
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4248236
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2707876
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70670801
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
6587879
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14320911
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27697284
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27697284
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1206995
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2597233
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
4982743
us-gaap Operating Expenses
OperatingExpenses
9951405
us-gaap Operating Expenses
OperatingExpenses
6845469
us-gaap Operating Income Loss
OperatingIncomeLoss
-9951405
us-gaap Operating Income Loss
OperatingIncomeLoss
-6845469
CY2016Q2 vktx Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
412050
CY2017Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
336656
CY2016Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
524977
CY2017Q2 vktx Amortization Of Financing Costs Equity Transactions
AmortizationOfFinancingCostsEquityTransactions
421781
vktx Amortization Of Financing Costs Equity Transactions
AmortizationOfFinancingCostsEquityTransactions
519960
CY2017Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1130
CY2016Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1813
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-188891
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-114740
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-434312
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-5171634
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-3692793
us-gaap Net Income Loss
NetIncomeLoss
-10393534
us-gaap Net Income Loss
NetIncomeLoss
-7279781
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1500
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6591
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5170134
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7481762
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
10426060
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4982743
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3578053
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
3578053
CY2017Q2 us-gaap Revenues
Revenues
0
CY2017Q2 vktx Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
570676
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2660
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-17275
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-442129
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
893
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7279197
vktx Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
848374
vktx Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
508597
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
767883
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
925634
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24118887
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17105374
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23240782
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13060576
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
49282
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
85011
vktx Amortization Of Non Cash Clinical Trial Costs
AmortizationOfNonCashClinicalTrialCosts
399587
us-gaap Share Based Compensation
ShareBasedCompensation
743497
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-53827
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
57153
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1168957
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
19609
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6525971
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
318149
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
768550
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
11700000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9201823
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4391380
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5159930
us-gaap Interest Paid
InterestPaid
205139
us-gaap Stock Issued1
StockIssued1
1800000
vktx Unpaid Deferred Initial Public Offering And Other Financing Costs
UnpaidDeferredInitialPublicOfferingAndOtherFinancingCosts
147804
vktx Unpaid Deferred Initial Public Offering And Other Financing Costs
UnpaidDeferredInitialPublicOfferingAndOtherFinancingCosts
381991
vktx Repayments Of Notes Payable In Stock
RepaymentsOfNotesPayableInStock
1200000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1273940
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6582278
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
62045
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
94861
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
13871
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
10943
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to determining the fair value of the debt conversion feature liability and accounting for certain commitments. Actual results could differ from those estimates.</p></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to certain of the prior years&#8217; financial statements to conform to the current year presentation.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p></div>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-09-24
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Three months or less
CY2016Q2 vktx Underwriters Grant Period Option
UnderwritersGrantPeriodOption
P45D
CY2016Q2 vktx Additional Warrants Granted To Underwriters
AdditionalWarrantsGrantedToUnderwriters
1125000
CY2016Q2 vktx Additional Warrants Sold As Result Of Over Allotment Exercise
AdditionalWarrantsSoldAsResultOfOverAllotmentExercise
1125000
CY2016Q2 us-gaap Share Price
SharePrice
0.01
CY2017Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
24387148
CY2016Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
17700774
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
23528353
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
13692258
CY2017Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
268261
CY2016Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
595400
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
287571
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
631682
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17973848
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14344831
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017Q2 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2016 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2017Q2 vktx Available For Sale Securities In Unrealized Gain Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableForSaleSecuritiesInUnrealizedGainPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0
CY2017Q2 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
19
CY2017Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
12156096
CY2017Q2 vktx Debt Conversion Feature Liability Noncurrent
DebtConversionFeatureLiabilityNoncurrent
894152
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
12594380
CY2016Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
731048
CY2017Q2 vktx Convertible Notes Payoff Value Current
ConvertibleNotesPayoffValueCurrent
2014472
CY2016 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.05
CY2016 vktx Debt Instrument Current Maturities Due Date
DebtInstrumentCurrentMaturitiesDueDate
2016
CY2017Q2 vktx Debt Instrument Current Maturity Date
DebtInstrumentCurrentMaturityDate
2018-05-21
vktx Date Of Registration Rights Agreement Amendment
DateOfRegistrationRightsAgreementAmendment
2016-01-22
CY2016Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7754286
CY2016Q2 vktx Underwriting Discounts Commissions And Other Offering Expenses
UnderwritingDiscountsCommissionsAndOtherOfferingExpenses
1631964
CY2014Q1 us-gaap Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
1000000
CY2014Q1 us-gaap Deferred Compensation Arrangement With Individual Exercise Price
DeferredCompensationArrangementWithIndividualExercisePrice
0.01
CY2014Q1 vktx Number Of Tranches
NumberOfTranches
2
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
168000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
633810
CY2015Q2 vktx Shares Repurchase Price Per Share
SharesRepurchasePricePerShare
0.00001
CY2015Q2 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
366190
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
61556
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7500000
CY2016Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7500000
CY2016Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.25
CY2016Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.50
CY2016Q2 vktx Additional Shares Offered Under Underwriting Agreement
AdditionalSharesOfferedUnderUnderwritingAgreement
1125000
CY2016Q2 vktx Class Of Warrants Or Rights Expiry Date
ClassOfWarrantsOrRightsExpiryDate
2021-04-13
CY2016Q2 vktx Over Allotment Option Exercised
OverAllotmentOptionExercised
1125000
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1125000
CY2016Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1283400
CY2016Q2 vktx Underwriting Discounts Commissions And Other Offering Expenses
UnderwritingDiscountsCommissionsAndOtherOfferingExpenses
111600
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
341258
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1594894
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
490245
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
883837
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
809534
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
98477
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
594069
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.28
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.23
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y0M22D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y7M28D
CY2017Q2 vktx Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0197
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.00
vktx Description Of Warrant
DescriptionOfWarrant
The warrant is exercisable for cash or on a cashless basis at a per share exercise price equal to $10.00 commencing on April 28, 2016, one year following the date of the prospectus filed with the SEC relating to the IPO, and expiring on April 28, 2020. The warrant also provides for registration rights upon request, under certain circumstances. The piggyback registration right provided in connection with the warrant will terminate on April 28, 2022.
vktx Warrant Expiration Date
WarrantExpirationDate
2022-04-28
vktx Initial Public Offering Expiration Date
InitialPublicOfferingExpirationDate
2020-04-28
vktx Class Of Warrants Or Rights Expiry Date
ClassOfWarrantsOrRightsExpiryDate
2021-04-13
CY2017Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
59389
CY2016Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
63010
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
121762
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
126021
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
104696
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
190337
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
295033

Files In Submission

Name View Source Status
0001564590-17-017021-index-headers.html Edgar Link pending
0001564590-17-017021-index.html Edgar Link pending
0001564590-17-017021.txt Edgar Link pending
0001564590-17-017021-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vktx-10q_20170630.htm Edgar Link pending
vktx-20170630.xml Edgar Link completed
vktx-20170630.xsd Edgar Link pending
vktx-20170630_cal.xml Edgar Link unprocessable
vktx-20170630_def.xml Edgar Link unprocessable
vktx-20170630_lab.xml Edgar Link unprocessable
vktx-20170630_pre.xml Edgar Link unprocessable
vktx-ex311_7.htm Edgar Link pending
vktx-ex312_6.htm Edgar Link pending
vktx-ex321_8.htm Edgar Link pending